Sign in Subscribe
Antiviral agents

RNA Viruses - Influenza A Virus Subtype H1N1 Research Uncovers New Treatment Insights

Strategic Insights

— 1 min read

Researchers at the University of Hong Kong have made significant progress in understanding the characteristics of influenza A virus subtype H1N1 and the effectiveness of various antiviral treatments. Investigating the virus's mutations and responses to different medications, the team assessed the efficacy of oseltamivir, molnupiravir, and baloxavir treatments in vitro and in vivo in mouse studies. Their findings indicate that combination therapy showed a significant antiviral effect, providing a reference for clinical treatment.

Key Takeaways:

  • The study used 41 seasonal influenza H1N1 strains from 2023, with the EC of oseltamivir significantly increased compared to a 2009 reference strain.
  • Correlation analysis revealed that the increase in EC was related to the HA and NA activities of the virus.
  • The antiviral effects of molnupiravir and baloxavir significantly inhibited virus replication, with combination treatment showing more potent and synergistic inhibitory effects in vitro.
  • In the mouse model, molnupiravir treatment effectively inhibited virus replication and lung inflammation but did not improve weight loss or reduce mortality.
  • The combination therapy molnupiravir/baloxavir proved to be more effective than monotherapy, with the lowest inflammatory response and highest survival rate.
  • The increase in HA and NA activities of seasonal influenza reduced the efficacy of oseltamivir treatment but retained the effectiveness of molnupiravir and baloxavir.
  • The study's findings provide insights into the development of effective treatments for influenza A virus subtype H1N1.

Statistics:

  • 41 seasonal influenza H1N1 strains were used in the study.
  • The EC of oseltamivir was significantly increased in 2023 compared to the 2009 reference strain.
  • Combination treatment of molnupiravir and baloxavir showed synergistic inhibitory effects in vitro.
  • In the mouse model, the combination therapy molnupiravir/baloxavir resulted in the lowest inflammatory response and highest survival rate.

Sources:

  • "Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies." Influenza and Other Respiratory Viruses, 2025; 19(10).
  • University of Hong Kong, Department of Medicine, Li Ka Shing Faculty of Medicine.
  • E. Schneeberg et al. "Molnupiravir and Baloxavir Combination Therapy in Mouse Models." Journal of Infectious Diseases, 2020; 222(10): 1631-1639.
  • Centers for Disease Control and Prevention (CDC). "Influenza (Flu)."

Read more